PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets
1.12.2020 19:00:00 EET | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina ® Focus Panel, AmpliSeq™ for Illumina ® Myeloid Panel and the TruSight™ Hereditary Cancer Panel. Adding these panels expands the existing relationship between Illumina and PierianDx, which currently covers use of the PierianDx platform to support genomic reporting in key global markets for the TruSight Oncology 500 portfolio.
Performing a comprehensive NGS test and delivering an accompanying genomic report were once only accomplished via a send-out test to a commercial lab. However, in performing tests as send-outs, healthcare organizations relinquish control over samples, turnaround time, and quality. The PierianDx platform enables healthcare organizations to accelerate their precision medicine programs by empowering them to create accurate, timely, and comprehensive clinical genomic reports in-house.
Illumina’s Senior Vice President and Chief Medical Officer Dr. Phil Febbo said: “PierianDx has demonstrated its commitment to best-in-class variant reporting solutions. We are excited to expand our partnership to cover the AmpliSeq™ suite of panels which are optimized for clinical cancer research.”
PierianDx develops Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical knowledgebase which transforms unstructured variant information into a highly structured and usable clinical genomic report. In use by academic medical centers, cancer centers, reference laboratories, and healthcare organizations worldwide, it helps users accurately and rapidly classify and interpret variants to produce a physician-ready report.
Lincoln Nadauld, Vice President and Chief of Precision Medicine and Genomics, Intermountain Healthcare, explains, “Our partnership with PierianDx has enabled us to advance our precision medicine program by enhancing the classification of variants, accelerating the identification of targeted therapies, and expanding clinical trial opportunities for our patients.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005427/en/
Contact information
Lisa Owen
lowen@pieriandx.com
Cell : 206-851-6246
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong20.7.2026 15:00:00 EEST | Press release
HistoSonics today announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city's position as a leading hub for physician education, clinical collaboration, and innovation in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720812810/en/ Pictured at the expanded Histotripsy Training Center in Hong Kong. Front row (left to right): Dr. Angus Yuen, Chief Medical Officer, Gleneagles Hospital Hong Kong; Prof. Albert Chan, Director of Liver Cancer Surgery Centre, Gleneagles Hospital Hong Kong; Dr. Kenneth Tsang, Regional Chief Executive Officer, IHH Healthcare North Asia, and Chief Executive Officer, Gleneagles Hospital Hong Kong; Dr. Vince Lau, Director of Interventional Radiology Centre, Gleneagles Hospital Hong Kong; Dr. Joe Herman, Vice President, Medical Affairs, HistoSonics. Back row (left to right): Jay Lee, APAC Regional Manager, HistoSonics; Eric Kwong, Hong Kong Sales Manager
Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program20.7.2026 14:29:00 EEST | Press release
In a world shaped by change and competing narratives, the ability to listen, question and engage in constructive dialogue has never been more critical. Through the Doha Debates Ambassador Program, a production of Qatar Foundation, young people from around the world are not only learning these skills, but actively applying them in their communities, careers and areas of study. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720452437/en/ Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program. Applications are open for young people from around the world to learn to engage and lead through truth-seeking conversations about complex global issues. (Photo: AETOSWire) This online educational program teaches young people from across the globe to debate differently. Rather than engaging in a Western-style battle of ideas, participants take an approach to dialogue that is grounded in the Majlis—a welcoming
Kinaxis Appoints Herb Yeh as Chief Financial Officer and Chief Strategy Officer20.7.2026 14:01:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today announced the appointment of Herb Yeh as Chief Financial Officer and Chief Strategy Officer, effective July 27, 2026. In this role, Yeh will oversee the global finance organization and corporate strategy operations at Kinaxis, leading all Finance, Accounting, Investor Relations, Corporate Strategy, and Corporate Development. He will work closely with the executive leadership team and Board of Directors to support disciplined execution, long-term growth, and shareholder value creation. "Herb has spent his career working with boards and management teams at their most critical inflection points in enterprise software, and we are thrilled to have him join Kinaxis," said Razat Gaurav, Chief Executive Officer of Kinaxis. "He has followed Kinaxis and the broader supply chain technology sector closely for more than a decade, and that depth of perspective, paired with his expertise advising companies on c
IFF Announces Agreement to Sell Its Portfolio of Botanical Extracts, Vitamins & Minerals and Food Enhancement Activities to SuanNutra, a Portfolio Company of Carbyne Equity Partners.20.7.2026 13:45:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, and health and biosciences — today announced that it has entered into an agreement with SuanNutra, a Carbyne Equity Partners portfolio company and global provider of science-backed branded and functional ingredients, to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including its range of natural colors and antioxidants and certain localized flavor activities in Peru. The portfolio serves a broad range of food, beverage and nutritional end markets through a comprehensive selection of customized solutions. “These businesses are highly respected, and we are confident they will continue to thrive under the ownership of SuanNutra and Carbyne,” said Erik Fyrwald, CEO IFF. “This transaction is another step in optimizing our portfolio and reinforces our focus on our core innovation-led businesses — Taste, Scent and Health & Biosciences — where we see the greatest opportunities to drive
NIQ Appoints Irina Stoian as Chief AI Commercial Officer20.7.2026 13:45:00 EEST | Press release
NIQ today announced that Irina Stoian has joined the company as Chief AI Commercial Officer, a newly created role designed to accelerate NIQ’s enterprise AI commercial strategy and help clients turn the company’s AI capabilities into business impact and growth. Stoian will help align Product, Technology, Commercial, Partnerships, and Marketing around a unified AI growth strategy. Her remit includes shaping commercial AI offerings, strategic partnerships, pricing and business models, and deeper integration of NIQ capabilities into client workflows. The appointment builds on NIQ’s broader AI strategy, which positions the company as a trusted intelligence infrastructure powering AI-driven commerce. Across its AI portfolio, including ConnectAI, NIQ Optiq™, and NIQ Cadence™, NIQ is expanding how clients access trusted data, intelligence, and AI-powered workflows. “AI is not a feature we are adding to NIQ; it is core to our product strategy,” said Jim Peck, Chief Executive Officer of NIQ. “I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom